Geron (NASDAQ:GERN) Stock Price Passes Above 200-Day Moving Average - What's Next?

Key Points

• Technical breakout: Geron’s shares rose above the 200-day moving average of $1.42, trading as high as $1.59 and last at $1.53 on volume of about 12.3 million shares, indicating short-term momentum.
• Company outlook: Geron is a clinical-stage biotech focused on the telomerase inhibitor imetelstat (Phase II/III), and recent FDA-panel-related headlines have boosted interest even as the firm missed quarterly expectations (EPS -$0.05 vs. -$0.03) and reports negative margins and ROE.
• Analyst stance: Ratings are mixed (2 Buy, 3 Hold, 2 Sell) with an overall consensus of "Hold" and an average price target of $2.17.

Geron Corporation (NASDAQ:GERN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.42 and traded as high as $1.59. Geron shares last traded at $1.53, with a volume of 12,308,582 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GERN. TD Cowen reissued a "buy" rating on shares of Geron in a research report on Thursday, January 29th. Weiss Ratings reissued a "sell (e+)" rating on shares of Geron in a research report on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $2.17.

Geron Trading Up 2.0%

The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.62 and a current ratio of 4.66. The stock has a market capitalization of $980.58 million, a PE ratio of -11.77 and a beta of 0.67. The stock has a 50-day moving average price of $1.63 and a two-hundred day moving average price of $1.42.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.02). Geron had a negative net margin of 46.65% and a negative return on equity of 28.86%. The company had revenue of $48.02 million for the quarter, compared to analysts' expectations of $50.43 million. As a group, equities analysts forecast that Geron Corporation will post -0.05 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. 55 North Private Wealth LLC purchased a new position in shares of Geron during the 4th quarter valued at about $29,000. LCM Capital Management Inc lifted its position in shares of Geron by 80.6% during the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC purchased a new position in shares of Geron during the 4th quarter valued at about $33,000. Caitong International Asset Management Co. Ltd raised its stake in Geron by 3,307.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 24,410 shares during the period. Finally, Swiss Life Asset Management Ltd raised its stake in Geron by 73.6% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 11,182 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation NASDAQ: GERN is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company's research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.